We also compared the antitumor activity between scriptaid and well-known HDAC inhibitor vorinostat, and both of them showed similar antiproliferation activity, implying that scriptaid could be a useful addition to the treatment options for patients with HCC (Figure 1A,B). This evidence concerns the gene HDAC9 and hepatocellular carcinoma.